Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

8.60SEK
19 Oct 2017
Change (% chg)

-1.40kr (-14.00%)
Prev Close
10.00kr
Open
10.00kr
Day's High
10.00kr
Day's Low
8.50kr
Volume
342,411
Avg. Vol
57,422
52-wk High
10.20kr
52-wk Low
4.64kr

Latest Key Developments (Source: Significant Developments)

Value of Karolinska Development's holdings in Umecrine Cognition increases
Monday, 16 Oct 2017 02:00am EDT 

Oct 16 (Reuters) - KAROLINSKA DEVELOPMENT AB ::REG-THE VALUE OF KAROLINSKA DEVELOPMENT'S HOLDINGS IN UMECRINE COGNITION INCREASES WITH SEK 196 MILLION OWING TO POSITIVE PHASE 1B DATA.‍BACKGROUND IS POSITIVE PHASE 1B DATA THAT UMECRINE COGNITION RECENTLY PRESENTED FOR ITS DRUG CANDIDATE GR3027​.‍THIS INCREASE IN BOOK VALUE WILL ALSO INCREASE RESULT FOR Q3 2017 WITH SEK 196 MILLION​.  Full Article

Karolinska Development's portfolio company secures financing
Wednesday, 4 Oct 2017 02:00am EDT 

Oct 4 (Reuters) - KAROLINSKA DEVELOPMENT AB ::REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY UMECRINE COGNITION SECURES FINANCING FOR CLINICAL DEVELOPMENT OF THE DRUG CANDIDATE GR3027 AGAINST SLEEP DISORDERS.‍HAS CLOSED A FINANCING ROUND RAISING SEK 20 MILLION​.  Full Article

Karolinska Development's portfolio company BioArctic to list on Nasdaq Stockholm
Wednesday, 13 Sep 2017 02:00am EDT 

Sept 13 (Reuters) - KAROLINSKA DEVELOPMENT AB ::REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY BIOARCTIC INTENDS TO LIST ON NASDAQ STOCKHOLM.‍KAROLINSKA DEVELOPMENT'S SHAREHOLDING IN BIOARCTIC AMOUNTS TO 3.17 PERCENT.​.  Full Article

Karolinska Development Q2 oper loss narrows to SEK 11.4 million
Wednesday, 30 Aug 2017 06:07am EDT 

Aug 30 (Reuters) - KAROLINSKA DEVELOPMENT AB ::SAID ON TUESDAY Q2 REVENUE SEK 560,000 VERSUS SEK 607,000 YEAR AGO.Q2 OPERATING LOSS SEK 11.4 MILLION VERSUS LOSS SEK 64.9 MILLION YEAR AGO.  Full Article

Karolinska Development appoints Fredrik Järrsten as CFO
Wednesday, 30 Aug 2017 01:50am EDT 

Aug 30 (Reuters) - KAROLINSKA DEVELOPMENT AB ::SAID ON TUESDAY APPOINTED FREDRIK JÄRRSTEN AS CFO.JÄRRSTEN WILL REPLACE CHRISTIAN TANGE.  Full Article

Karolinska notes the planned listing of Xspray on Nasdaq First North
Friday, 25 Aug 2017 07:00am EDT 

Aug 25 (Reuters) - KAROLINSKA DEVELOPMENT AB ::REG-KAROLINSKA DEVELOPMENT NOTES THE PLANNED LISTING OF XSPRAY AB ON NASDAQ FIRST NORTH.IN CONJUNCTION WITH XSPRAY'S PLANNED LISTING ON NASDAQ FIRST NORTH A NEW SHARE ISSUE IS BEING MADE WHICH, AT FULL SUBSCRIPTION, WOULD GENERATE SEK 132 MILLION BEFORE ISSUE COSTS​.‍NEW ISSUE IS BEING DIRECTED TO PUBLIC IN SWEDEN AND INSTITUTIONAL INVESTORS​.‍SUBSCRIPTION PERIOD FOR SHARE OFFER WILL RUN FROM 28 AUGUST - 11 SEPTEMBER 2017​.  Full Article

Karolinska Development Q1 net loss narrow to SEK 25.2 mln
Wednesday, 17 May 2017 01:10am EDT 

May 17 (Reuters) - KAROLINSKA DEVELOPMENT AB ::SAID ON TUESDAY Q1 REVENUE WAS SEK 0.6 MLN VS SEK 0.6 MLN YR AGO.NET LOSS SEK 25.2 MLN VS LOSS SEK 100.1 MLN YR AGO.  Full Article

Karolinska Development: Chairman and CEO to step down, Viktor Drvota new CEO
Thursday, 20 Apr 2017 02:03am EDT 

April 20 (Reuters) - KAROLINSKA DEVELOPMENT AB :KAROLINSKA DEVELOPMENT ANNOUNCES CHAIRMAN BO JESPER HANSEN AND CEO JIM VAN HEUSDEN'S DECISION TO STEP DOWN, AND THE PROMOTION OF VIKTOR DRVOTA TO CEO.CEO, JIM VAN HEUSDEN, WILL FORMALLY LEAVE COMPANY AT END OF OCTOBER 2017..BO JESPER HANSEN, CHAIRMAN, INFORMS THAT HE WILL NOT STAND FOR RE-ELECTION AT 2017 ANNUAL GENERAL MEETING.CEO, JIM VAN HEUSDEN, TENDERS HIS RESIGNATION AND WILL FORMALLY LEAVE COMPANY AT END OF OCTOBER 2017.PROMOTION OF VIKTOR DRVOTA AS COMPANY'S CHIEF EXECUTIVE OFFICER, EFFECTIVE JUNE 1 2017.  Full Article

Karolinska Development announces outcome of set-off issue
Wednesday, 5 Apr 2017 02:01am EDT 

KAROLINSKA DEVELOPMENT AB : REG-KAROLINSKA DEVELOPMENT ANNOUNCES OUTCOME OF SET-OFF ISSUE . CONVERTIBLE HOLDERS ACCEPTED TO OFFSET SEK 67 MILLION OF COMPANY'S CONVERTIBLE DEBT . SHARE CAPITAL WILL INCREASE BY SEK 5.4 MILLION FROM SEK 26.7 MILLION TO SEK 32.2 MILLION .SEB EMISSIONER ACTED AS ISSUING AGENT IN CONNECTION WITH SET-OFF ISSUE.  Full Article

Karolinska Development: research collaboration with Memorial Sloan Kettering Cancer Center
Wednesday, 22 Mar 2017 08:00am EDT 

Karolinska Development AB : Karolinska Development company Aprea Therapeutics announces research collaboration with Memorial Sloan Kettering Cancer Center .Announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor protein p53 by APR-246.  Full Article

BRIEF-Value of Karolinska Development's holdings in Umecrine Cognition increases

* REG-THE VALUE OF KAROLINSKA DEVELOPMENT'S HOLDINGS IN UMECRINE COGNITION INCREASES WITH SEK 196 MILLION OWING TO POSITIVE PHASE 1B DATA